Trials / Recruiting
RecruitingNCT05859074
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.
Conditions
- Cutaneous Squamous Cell Carcinoma
- SCC - Squamous Cell Carcinoma
- Basal Cell Carcinoma
- BCC
- BCC - Basal Cell Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Sebaceous Carcinoma
- Extramammary Paget Disease
- Kaposi Sarcoma
- Head and Neck Squamous Cell Carcinoma
- HNSCC
- Adnexal Carcinoma
- Angiosarcoma
- Cutaneous Neoplasm
- Advanced Cancer
- Metastatic Cancer
- Refractory Cancer
- Solid Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MQ719 | Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval. |
| DRUG | Pembrolizumab | Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval. |
Timeline
- Start date
- 2023-05-04
- Primary completion
- 2028-05-04
- Completion
- 2028-05-04
- First posted
- 2023-05-15
- Last updated
- 2025-12-03
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05859074. Inclusion in this directory is not an endorsement.